search
Back to results

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

Primary Purpose

Breast Cancer

Status
Active
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Trastuzumab deruxtecan
Capecitabine
Lapatinib
Trastuzumab
Sponsored by
Daiichi Sankyo, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Breast Cancer focused on measuring Breast Cancer, Metastatic breast cancer, DS 8201a, DESTINY - Breast 02

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Is the age of majority in their country

  • Has pathologically documented breast cancer that:

    1. is unresectable or metastatic
    2. has confirmed HER2-positive expression as determined according to American Society of Clinical Oncology - College of American Pathologists guidelines evaluated at a central laboratory
    3. was previously treated with ado-trastuzumab emtansine (T-DM1)
  • Has documented radiologic progression (during or after most recent treatment or within 6 months after completing adjuvant therapy)
  • Is HER2 positive as confirmed by central laboratory assessment of most recent tumor tissue sample available. If archived tissue is not available, agrees to provide a fresh biopsy.

  • Male and female participants of reproductive/childbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and for at least:

    1. 7 months after the last dose of DS-8201a (females); 4.5 months after last dose of DS-8201a (males)
    2. 6 months after the last dose of lapatinib/capecitabine for female participants (3 months for male participants)
    3. 7 months after the last dose of trastuzumab/capecitabine
  • Has adequate hematopoietic, renal and hepatic functions

Exclusion Criteria:

  • Has previously participated in an antibody drug conjugate study sponsored by Daiichi Sankyo. Prior treatment in the adjuvant/neo-adjuvant setting would be allowed if progression of disease did not occur within 12 months of end of adjuvant therapy
  • Has had prior treatment with capecitabine
  • Has uncontrolled or significant cardiovascular disease
  • Has a history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
  • Has active central nervous system (CNS) metastases

Sites / Locations

  • Ironwood Cancer Research Centers
  • UCLA Hematology Oncology - Main Site
  • Pacific Cancer Care
  • Sharp Memorial Hospital
  • Innovative Clinical Research Institute
  • Smilow Cancer Hospital at Yale New Haven
  • Washington Cancer Institute
  • Florida Cancer Specialists-Broadway
  • Piedmont Cancer Institute, PC
  • Kapiolani Medical Center for Women and Children/Univ of HI
  • Loyola University Health System
  • Community Hospital
  • Norton Cancer Institute
  • Maine Center for Cancer Medicine
  • University of Maryland
  • Beth Israel Deaconess Medical Center
  • Dana Farber Cancer Institute
  • Henry Ford Hospital
  • Cornell-Beshore Cancer Institute
  • Saint Luke's Cancer Institute
  • Health Midwest Ventures Group, Inc d/b/a HCA MidAmerica Division, LLC
  • Washington University
  • North Shore Hematology Oncology Associates, PC
  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
  • University of Cincinnati Medical Center
  • Cleveland Clinic Main Campus
  • The Ohio State University
  • Dayton Physicians, LLC
  • Abramson Cancer Center
  • Allegheny General Hospital
  • UPMC Cancer Center
  • Tennessee Oncology, PLLC Chattanooga
  • The West Clinic
  • SCRI - Tennessee Oncology
  • UT Southwestern Medical Center
  • MD Anderson Cancer Center
  • The Methodist Hospital Research Institute
  • The University of Texas Health Science Center at Tyler
  • Community Cancer Trials of Utah
  • Virginia Cancer Specialists, PC
  • MultiCare Health System Institute for Research and Innovation
  • St Vincent's Hospital Sydney
  • Liverpool Hospital
  • Macquarie University Hospital
  • The Tweed Hospital
  • Princess Alexandra Hospital
  • Ashford Cancer Centre Research
  • Box Hill Hospital
  • Frankston Hospital
  • Peninsula and South Eastern Haematology & Oncology Group
  • Austin Health
  • Peter MacCallum Cancer Centre
  • Sunshine Hospital
  • South West Oncology
  • Ballarat Oncology & Haematology Service
  • St John of God Subiaco Hospital
  • Calvary North Adelaide Hospital
  • Universitair Ziekenhuis Brussel
  • Cliniques Universitaires Saint-Luc
  • AZ Maria Middelares
  • Az Groeninge
  • UZ Leuven
  • CHU UCL Namur site de Sainte Elisabeth
  • NOB - Núcleo de Oncologia da Bahia
  • AMO - Assistência Multidisciplinar em Oncologia
  • Pronutrir
  • Oncobio Servicos de Saude
  • HGB - Hospital Giovanni Battista - Mãe de Deus Center
  • CliniOnco - Tratamento Integrado do Câncer
  • Escosteguy Barrios, Carlos Henrique
  • Hospital Nossa Senhora da Conceição
  • Clínica de Neoplasias Litoral Ltda.
  • CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
  • IBCC - Instituto Brasileiro de Controle do Câncer
  • COI - Clínicas Oncológicas Integradas
  • Sociedade Beneficiente de Senhoras Hospital Sírio Libanês
  • A. C. Camargo Cancer Center
  • Fakultni nemocnice Brno
  • Fakultni nemocnice Olomouc
  • Fakultni nemocnice v Motole
  • Nemocnice Na Bulovce
  • Hôpital Nord - CHU Marseille
  • Centre François Baclesse
  • CARIO - Centre Armoricain de Radiothérapie, Imagerie médicale et Oncologie
  • Centre Georges François Leclerc
  • CHU Besançon - Hôpital Jean Minjoz
  • CHU Brest - Hôpital Morvan
  • Hôpital Privé d'Antony
  • Centre René Huguenin
  • Clinique Clementville
  • Institut Régional du Cancer de Montpellier
  • CRLCC Eugene Marquis
  • Centre Oscar Lambret
  • Centre de cancerologie les Dentellieres
  • Institut Curie - site de Paris
  • Centre Hospitalier de la côte Basque
  • Centre Hospitalier Lyon Sud
  • Clinique Victor Hugo - Centre Jean Bernard
  • Centre Henri Becquerel
  • Institut Sainte Catherine
  • Institut Gustave Roussy
  • Institut Régional du Cancer de Montpellier
  • Institut Curie - site de Paris
  • Hopital Tenon
  • Klinikum rechts der Isar der TU Muenchen
  • Marienhospital Bottrop gGmbH
  • Universitaetsklinikum Schleswig-Holstein - Campus Luebeck
  • Helios-Kliniken Berlin-Buch
  • Universitaetsklinikum Duesseldorf AoeR
  • Universitaetsklinikum Erlangen
  • Kliniken Koeln
  • Universitaetsklinikum Leipzig AoeR
  • Klinikum der Universitaet Muenchen - Campus Grosshardern
  • Universitaetsklinikum Muenster
  • Haematologisch-Onkologische Schwerpunktpraxis
  • 251 General Air Force Hospital
  • General Hospital of Athens "Alexandra"
  • General Oncology Hospital of Kifissia " Agioi Anargyroi"
  • University General Hospital of Heraklion
  • Euromedica General Clinic Thessaloniki
  • Rambam Health Care Center
  • Shaare Zedek Medical Center
  • Hadassah University Hospital - Ein Kerem
  • Sapir Medical Center, Meir Hospital
  • Rabin Medical Center-Beilinson Campus
  • Chaim Sheba Medical Center
  • Tel Aviv Sourasky Medical Center
  • Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo)
  • IRCCS Centro di Riferimento Oncologico
  • Ospedale Sacro Cuore Don Calabria
  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
  • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi
  • Azienda Ospedaliera Universitaria Arcispedale Sant'Anna
  • Istituto Nazionale per la Ricerca sul Cancro di Genova
  • Azienda Ospealiera della Provincia di Lecco
  • Azienda Ospedaliera Ospedali Riuniti Papardo-Piemonte
  • Ospedale San Raffaele
  • Fondazione IRCCS Istituto Nazionale dei Tumori
  • IEO Istituto Europeo di Oncologia
  • A.O.U. Policlinico di Modena
  • Istituto Nazionale Tumori Fondazione G. Pascale
  • IOV - Istituto Oncologico Veneto IRCCS
  • Azienda Ospedaliero Universitaria di Parma
  • Fondazione IRCCS Policlinico San Matteo
  • Azienda Ospedaliero Universitaria Pisana
  • Azienda Ospedaliera Città della Salute e della Scienza di Torino
  • Fukushima Medical University Hospital
  • Kindai University Hospital
  • Kindai University Hospital
  • National Cancer Center Hospital
  • NHO Shikoku Cancer Center
  • NHO Kyushu Cancer Center
  • Hiroshima City Hiroshima Citizens Hospital
  • NHO Hokkaido Cancer Center
  • Hyōgo College of Medicine Hospital
  • St. Marianna University School of Medicine Hospital
  • Kanagawa Cancer Center
  • Kyoto University Hospital
  • Tohoku University Hospital
  • Aichi Cancer Center Hospital
  • Niigata Cancer Center Hospital
  • Okayama University Hospital
  • NHO Osaka National Hospital
  • Osaka International Cancer Institute
  • Saitama Cancer Center
  • Shizuoka Cancer Center
  • Toranomon Hospital
  • The Cancer Institute Hospital of JFCR
  • Tokyo Medical University Hospital
  • Chungbuk National University Hospital
  • Inha University Hospital
  • Seoul National University Bundang Hospital
  • The Catholic University of Korea, St. Vincent's Hospital
  • Ajou University Hospital
  • Kyungpook National University Chilgok Hospital
  • National Cancer Center
  • Korea University Anam Hospital
  • Seoul National University Hospital
  • Severance Hospital, Yonsei University
  • Asan Medical Center
  • Samsung Medical Center
  • The Catholic University of Korea, Seoul St. Mary's Hospital
  • ICO Badalona - Hospital Universitari Germans Trias i Pujol
  • ICO l'Hospitalet - Hospital Duran i Reynals
  • Hospital de Especialidades de Jerez de la Frontera
  • Complejo Hospitalario Universitario A Coruña
  • Hospital Universitario de Canarias
  • Hospital Infanta Cristina
  • Hospital Quironsalud Barcelona
  • Hospital Universitari Vall d'Hebron
  • Hospital Clinic de Barcelona
  • Hospital del Mar
  • Hospital Universitari Arnau de Vilanova
  • Hospital General Universitario Gregorio Marañon
  • MD Anderson Cancer Centre
  • Hospital Universitario Clinico San Carlos
  • Hospital Clinico Universitario Virgen de la Victoria
  • Hospital Universitario de Salamanca
  • Hospital Universitario Virgen Macarena
  • Hospital Universitario Virgen del Rocio
  • Instituto Valenciano de Oncologia IVO
  • Hospital Universitario Miguel Servet
  • Acibadem Adana Hospital
  • Adana Numune Training and Research Hospital
  • Ankara Yildirim Beyazit Uni. Med. Fac.Ankara City Hospital
  • Akdeniz University Medical Faculty
  • Uludag University Medical Faculty
  • Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty
  • Bakirkoy Dr. Sadi Konuk Teaching and Research Hospital
  • Medipol University Medical Faculty
  • Medical Park Goztepe Hospital
  • Istanbul Medeniyet Uni Goztepe Training & Research Hospital
  • Kartal Lutfi Kirdar Research and Training Hospital
  • Izmir Medicalpark Hospital
  • Konya Necmettin Erbakan University Meram Faculty of Medicine
  • Sakarya Traning and Research Hospital
  • Medical Park Samsun Hastanesi
  • Namik Kemal University
  • Royal Cornwall Hospital
  • Royal Devon and Exeter Hospital (Wonford)
  • Derriford Hospital
  • Aberdeen Royal Infirmary
  • Queen Mary University of London
  • University College London Hospitals
  • Sarah Cannon Research Institute UK
  • Western General Hospital
  • Nottingham University Hospitals City Campus

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Active Comparator

Arm Label

Trastuzumab deruxtecan (DS-8201a)

Trastuzumab+capecitabine

Lapatinib+capecitabine

Arm Description

HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to treatment with DS-8201a

HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Trastuzumab/capecitabine

HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Lapatinib/capecitabine

Outcomes

Primary Outcome Measures

Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
Progression-free survival (PFS) by BICR was defined as the time from the date of randomization to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause.

Secondary Outcome Measures

Overall Survival (OS) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there is no death reported for a subject before the data cutoff for OS analysis, OS will be censored at the last contact date at which the subject is known to be alive.
Percentage of Participants With Objective Response Rate (ORR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
The Objective Response Rate (ORR) was defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by BICR and investigator assessment based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on BICR and Investigator Assessment is reported.
Duration of Response (DoR) Based on BICR in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
Duration of Response (DoR) was defined as the time from the date of the first documentation of objective response (complete response [CR] or partial response [PR]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. DoR in participants with confirmed CR/PR based on BICR and investigator assessment is reported.
Progression-Free Survival (PFS) Based on Investigator Assessment in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
Progression-free survival (PFS) by investigator assessment was defined as the time from the date of randomization to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause.

Full Information

First Posted
April 13, 2018
Last Updated
May 30, 2023
Sponsor
Daiichi Sankyo, Inc.
Collaborators
Daiichi Sankyo Co., Ltd., AstraZeneca
search

1. Study Identification

Unique Protocol Identification Number
NCT03523585
Brief Title
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Official Title
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
August 1, 2018 (Actual)
Primary Completion Date
June 30, 2022 (Actual)
Study Completion Date
September 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Daiichi Sankyo, Inc.
Collaborators
Daiichi Sankyo Co., Ltd., AstraZeneca

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study will compare DS 8201a to standard treatment. Participants must have HER2 breast cancer that has been treated before. Their cancer: cannot be removed by an operation has spread to other parts of the body
Detailed Description
The study is designed to compare DS 8201a versus standard of care (investigator's choice) in subjects with unresectable and/or metastatic breast cancer previously treated with T-DM1.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer
Keywords
Breast Cancer, Metastatic breast cancer, DS 8201a, DESTINY - Breast 02

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
608 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Trastuzumab deruxtecan (DS-8201a)
Arm Type
Experimental
Arm Description
HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to treatment with DS-8201a
Arm Title
Trastuzumab+capecitabine
Arm Type
Active Comparator
Arm Description
HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Trastuzumab/capecitabine
Arm Title
Lapatinib+capecitabine
Arm Type
Active Comparator
Arm Description
HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Lapatinib/capecitabine
Intervention Type
Drug
Intervention Name(s)
Trastuzumab deruxtecan
Other Intervention Name(s)
DS-8201a, T-DXd
Intervention Description
DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as intravenous (IV) dose
Intervention Type
Drug
Intervention Name(s)
Capecitabine
Other Intervention Name(s)
Investigator's Choice Comparative Therapy
Intervention Description
Investigator's choice Standard of Care when combined with trastuzumab or lapatinib
Intervention Type
Drug
Intervention Name(s)
Lapatinib
Other Intervention Name(s)
Investigator's Choice Comparative Therapy
Intervention Description
Investigator's choice Standard of Care when combined with capecitabine
Intervention Type
Drug
Intervention Name(s)
Trastuzumab
Other Intervention Name(s)
Investigator's Choice Comparative Therapy
Intervention Description
Investigator's choice Standard of Care when combined with capecitabine
Primary Outcome Measure Information:
Title
Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
Description
Progression-free survival (PFS) by BICR was defined as the time from the date of randomization to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause.
Time Frame
Baseline up to 46 months postdose
Secondary Outcome Measure Information:
Title
Overall Survival (OS) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
Description
Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there is no death reported for a subject before the data cutoff for OS analysis, OS will be censored at the last contact date at which the subject is known to be alive.
Time Frame
Baseline up to 46 months postdose
Title
Percentage of Participants With Objective Response Rate (ORR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
Description
The Objective Response Rate (ORR) was defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by BICR and investigator assessment based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on BICR and Investigator Assessment is reported.
Time Frame
Baseline up to 46 months postdose
Title
Duration of Response (DoR) Based on BICR in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
Description
Duration of Response (DoR) was defined as the time from the date of the first documentation of objective response (complete response [CR] or partial response [PR]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. DoR in participants with confirmed CR/PR based on BICR and investigator assessment is reported.
Time Frame
Baseline up to 46 months postdose
Title
Progression-Free Survival (PFS) Based on Investigator Assessment in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
Description
Progression-free survival (PFS) by investigator assessment was defined as the time from the date of randomization to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause.
Time Frame
Up to 46 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Is the age of majority in their country Has pathologically documented breast cancer that: is unresectable or metastatic has confirmed HER2-positive expression as determined according to American Society of Clinical Oncology - College of American Pathologists guidelines evaluated at a central laboratory was previously treated with ado-trastuzumab emtansine (T-DM1) Has documented radiologic progression (during or after most recent treatment or within 6 months after completing adjuvant therapy) Is HER2 positive as confirmed by central laboratory assessment of most recent tumor tissue sample available. If archived tissue is not available, agrees to provide a fresh biopsy. Male and female participants of reproductive/childbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and for at least: 7 months after the last dose of DS-8201a (females); 4.5 months after last dose of DS-8201a (males) 6 months after the last dose of lapatinib/capecitabine for female participants (3 months for male participants) 7 months after the last dose of trastuzumab/capecitabine Has adequate hematopoietic, renal and hepatic functions Exclusion Criteria: Has previously participated in an antibody drug conjugate study sponsored by Daiichi Sankyo. Prior treatment in the adjuvant/neo-adjuvant setting would be allowed if progression of disease did not occur within 12 months of end of adjuvant therapy Has had prior treatment with capecitabine Has uncontrolled or significant cardiovascular disease Has a history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening Has active central nervous system (CNS) metastases
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Global Team Leader
Organizational Affiliation
Daiichi Sankyo, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Ironwood Cancer Research Centers
City
Chandler
State/Province
Arizona
ZIP/Postal Code
85224-5665
Country
United States
Facility Name
UCLA Hematology Oncology - Main Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Facility Name
Pacific Cancer Care
City
Monterey
State/Province
California
ZIP/Postal Code
93940
Country
United States
Facility Name
Sharp Memorial Hospital
City
San Diego
State/Province
California
ZIP/Postal Code
92123
Country
United States
Facility Name
Innovative Clinical Research Institute
City
Whittier
State/Province
California
ZIP/Postal Code
90603
Country
United States
Facility Name
Smilow Cancer Hospital at Yale New Haven
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06510
Country
United States
Facility Name
Washington Cancer Institute
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20010
Country
United States
Facility Name
Florida Cancer Specialists-Broadway
City
Fort Myers
State/Province
Florida
ZIP/Postal Code
33901
Country
United States
Facility Name
Piedmont Cancer Institute, PC
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30318
Country
United States
Facility Name
Kapiolani Medical Center for Women and Children/Univ of HI
City
Honolulu
State/Province
Hawaii
ZIP/Postal Code
96826
Country
United States
Facility Name
Loyola University Health System
City
Maywood
State/Province
Illinois
ZIP/Postal Code
60153
Country
United States
Facility Name
Community Hospital
City
Munster
State/Province
Indiana
ZIP/Postal Code
46321
Country
United States
Facility Name
Norton Cancer Institute
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40207
Country
United States
Facility Name
Maine Center for Cancer Medicine
City
Scarborough
State/Province
Maine
ZIP/Postal Code
04074
Country
United States
Facility Name
University of Maryland
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Name
Dana Farber Cancer Institute
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Name
Henry Ford Hospital
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Facility Name
Cornell-Beshore Cancer Institute
City
Joplin
State/Province
Missouri
ZIP/Postal Code
64804
Country
United States
Facility Name
Saint Luke's Cancer Institute
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64111
Country
United States
Facility Name
Health Midwest Ventures Group, Inc d/b/a HCA MidAmerica Division, LLC
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64132
Country
United States
Facility Name
Washington University
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
North Shore Hematology Oncology Associates, PC
City
East Setauket
State/Province
New York
ZIP/Postal Code
11733
Country
United States
Facility Name
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Facility Name
University of Cincinnati Medical Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45267-0502
Country
United States
Facility Name
Cleveland Clinic Main Campus
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Facility Name
The Ohio State University
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43235
Country
United States
Facility Name
Dayton Physicians, LLC
City
Kettering
State/Province
Ohio
ZIP/Postal Code
45409
Country
United States
Facility Name
Abramson Cancer Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
Allegheny General Hospital
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15212
Country
United States
Facility Name
UPMC Cancer Center
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
Tennessee Oncology, PLLC Chattanooga
City
Chattanooga
State/Province
Tennessee
ZIP/Postal Code
37404
Country
United States
Facility Name
The West Clinic
City
Germantown
State/Province
Tennessee
ZIP/Postal Code
38138
Country
United States
Facility Name
SCRI - Tennessee Oncology
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Facility Name
UT Southwestern Medical Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390-8857
Country
United States
Facility Name
MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
The Methodist Hospital Research Institute
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
The University of Texas Health Science Center at Tyler
City
Tyler
State/Province
Texas
ZIP/Postal Code
75708
Country
United States
Facility Name
Community Cancer Trials of Utah
City
Ogden
State/Province
Utah
ZIP/Postal Code
84405
Country
United States
Facility Name
Virginia Cancer Specialists, PC
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Facility Name
MultiCare Health System Institute for Research and Innovation
City
Tacoma
State/Province
Washington
ZIP/Postal Code
98405
Country
United States
Facility Name
St Vincent's Hospital Sydney
City
Darlinghurst
State/Province
New South Wales
ZIP/Postal Code
2010
Country
Australia
Facility Name
Liverpool Hospital
City
Liverpool
State/Province
New South Wales
ZIP/Postal Code
2170
Country
Australia
Facility Name
Macquarie University Hospital
City
Sydney
State/Province
New South Wales
ZIP/Postal Code
2109
Country
Australia
Facility Name
The Tweed Hospital
City
Tweed Heads
State/Province
New South Wales
ZIP/Postal Code
2485
Country
Australia
Facility Name
Princess Alexandra Hospital
City
Woolloongabba
State/Province
Queensland
ZIP/Postal Code
4102
Country
Australia
Facility Name
Ashford Cancer Centre Research
City
Kurralta Park
State/Province
South Australia
ZIP/Postal Code
5037
Country
Australia
Facility Name
Box Hill Hospital
City
Box Hill
State/Province
Victoria
ZIP/Postal Code
3128
Country
Australia
Facility Name
Frankston Hospital
City
Frankston
State/Province
Victoria
ZIP/Postal Code
3199
Country
Australia
Facility Name
Peninsula and South Eastern Haematology & Oncology Group
City
Frankston
State/Province
Victoria
ZIP/Postal Code
3199
Country
Australia
Facility Name
Austin Health
City
Heidelberg
State/Province
Victoria
ZIP/Postal Code
3084
Country
Australia
Facility Name
Peter MacCallum Cancer Centre
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3000
Country
Australia
Facility Name
Sunshine Hospital
City
Saint Albans
State/Province
Victoria
ZIP/Postal Code
3021
Country
Australia
Facility Name
South West Oncology
City
Warrnambool
State/Province
Victoria
ZIP/Postal Code
3280
Country
Australia
Facility Name
Ballarat Oncology & Haematology Service
City
Wendouree
State/Province
Victoria
ZIP/Postal Code
3355
Country
Australia
Facility Name
St John of God Subiaco Hospital
City
Subiaco
State/Province
Western Australia
ZIP/Postal Code
6008
Country
Australia
Facility Name
Calvary North Adelaide Hospital
City
Bruce
ZIP/Postal Code
2614
Country
Australia
Facility Name
Universitair Ziekenhuis Brussel
City
Bruxelles
ZIP/Postal Code
1090
Country
Belgium
Facility Name
Cliniques Universitaires Saint-Luc
City
Bruxelles
ZIP/Postal Code
1200
Country
Belgium
Facility Name
AZ Maria Middelares
City
Gent
ZIP/Postal Code
9000
Country
Belgium
Facility Name
Az Groeninge
City
Kortrijk
ZIP/Postal Code
8500
Country
Belgium
Facility Name
UZ Leuven
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Name
CHU UCL Namur site de Sainte Elisabeth
City
Namur
ZIP/Postal Code
5000
Country
Belgium
Facility Name
NOB - Núcleo de Oncologia da Bahia
City
Salvador
State/Province
Bahia
ZIP/Postal Code
40170-110
Country
Brazil
Facility Name
AMO - Assistência Multidisciplinar em Oncologia
City
Salvador
State/Province
Bahia
ZIP/Postal Code
41950-640
Country
Brazil
Facility Name
Pronutrir
City
Fortaleza
State/Province
Ceará
ZIP/Postal Code
60810-180
Country
Brazil
Facility Name
Oncobio Servicos de Saude
City
Nova Lima
State/Province
Minas Gerais
ZIP/Postal Code
34000
Country
Brazil
Facility Name
HGB - Hospital Giovanni Battista - Mãe de Deus Center
City
Porto Alegre
State/Province
Rio Grande Do Sul
ZIP/Postal Code
90110-270
Country
Brazil
Facility Name
CliniOnco - Tratamento Integrado do Câncer
City
Porto Alegre
State/Province
Rio Grande Do Sul
ZIP/Postal Code
90430-090
Country
Brazil
Facility Name
Escosteguy Barrios, Carlos Henrique
City
Porto Alegre
State/Province
Rio Grande Do Sul
ZIP/Postal Code
90610-000
Country
Brazil
Facility Name
Hospital Nossa Senhora da Conceição
City
Porto Alegre
State/Province
Rio Grande Do Sul
ZIP/Postal Code
91350-200
Country
Brazil
Facility Name
Clínica de Neoplasias Litoral Ltda.
City
Itajaí
State/Province
Santa Catarina
ZIP/Postal Code
88301-220
Country
Brazil
Facility Name
CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
City
Santo André
State/Province
Sao Paulo
ZIP/Postal Code
09060-650
Country
Brazil
Facility Name
IBCC - Instituto Brasileiro de Controle do Câncer
City
São Paulo
State/Province
Sao Paulo
ZIP/Postal Code
03102-002
Country
Brazil
Facility Name
COI - Clínicas Oncológicas Integradas
City
Rio De Janeiro
ZIP/Postal Code
22793-080
Country
Brazil
Facility Name
Sociedade Beneficiente de Senhoras Hospital Sírio Libanês
City
São Paulo
ZIP/Postal Code
01308
Country
Brazil
Facility Name
A. C. Camargo Cancer Center
City
São Paulo
ZIP/Postal Code
01509-900
Country
Brazil
Facility Name
Fakultni nemocnice Brno
City
Brno
ZIP/Postal Code
625 00
Country
Czechia
Facility Name
Fakultni nemocnice Olomouc
City
Olomouc
ZIP/Postal Code
775 20
Country
Czechia
Facility Name
Fakultni nemocnice v Motole
City
Prague 5
ZIP/Postal Code
150 06
Country
Czechia
Facility Name
Nemocnice Na Bulovce
City
Praha
ZIP/Postal Code
180 81
Country
Czechia
Facility Name
Hôpital Nord - CHU Marseille
City
Marseille cedex 20
State/Province
Bouches-du-Rhône
ZIP/Postal Code
13915
Country
France
Facility Name
Centre François Baclesse
City
Caen Cedex 05
State/Province
Calvados
ZIP/Postal Code
14076
Country
France
Facility Name
CARIO - Centre Armoricain de Radiothérapie, Imagerie médicale et Oncologie
City
Plérin
State/Province
Cotes d'Armor
ZIP/Postal Code
22190
Country
France
Facility Name
Centre Georges François Leclerc
City
Dijon cedex
State/Province
Côte-d'Or
ZIP/Postal Code
21079
Country
France
Facility Name
CHU Besançon - Hôpital Jean Minjoz
City
Besançon
State/Province
Doubs
ZIP/Postal Code
25030
Country
France
Facility Name
CHU Brest - Hôpital Morvan
City
Brest Cedex
State/Province
Finistere
ZIP/Postal Code
29609
Country
France
Facility Name
Hôpital Privé d'Antony
City
Antony
State/Province
Hauts De Seine
ZIP/Postal Code
92160
Country
France
Facility Name
Centre René Huguenin
City
Saint-Cloud
State/Province
Hauts De Seine
ZIP/Postal Code
92110
Country
France
Facility Name
Clinique Clementville
City
Montpellier
State/Province
Herault
ZIP/Postal Code
34070
Country
France
Facility Name
Institut Régional du Cancer de Montpellier
City
Montpellier
State/Province
Herault
ZIP/Postal Code
34298
Country
France
Facility Name
CRLCC Eugene Marquis
City
Rennes cedex
State/Province
Ille Et Vilaine
ZIP/Postal Code
35042
Country
France
Facility Name
Centre Oscar Lambret
City
Lille cedex
State/Province
Nord
ZIP/Postal Code
59020
Country
France
Facility Name
Centre de cancerologie les Dentellieres
City
Valenciennes
State/Province
Nord
ZIP/Postal Code
59300
Country
France
Facility Name
Institut Curie - site de Paris
City
Paris Cedex 05
State/Province
Paris
ZIP/Postal Code
75005
Country
France
Facility Name
Centre Hospitalier de la côte Basque
City
Bayonne Cedex
State/Province
Pyrenees Atlantiques
ZIP/Postal Code
64109
Country
France
Facility Name
Centre Hospitalier Lyon Sud
City
Pierre Benite cedex
State/Province
Rhone
ZIP/Postal Code
69495
Country
France
Facility Name
Clinique Victor Hugo - Centre Jean Bernard
City
Le Mans Cedex 02
State/Province
Sarthe
ZIP/Postal Code
72015
Country
France
Facility Name
Centre Henri Becquerel
City
Rouen
State/Province
Seine Maritime
ZIP/Postal Code
76038
Country
France
Facility Name
Institut Sainte Catherine
City
Avignon Cedex 9
State/Province
Vaculuse
ZIP/Postal Code
84918
Country
France
Facility Name
Institut Gustave Roussy
City
Villejuif cedex
State/Province
Val De Marne
ZIP/Postal Code
94805
Country
France
Facility Name
Institut Régional du Cancer de Montpellier
City
Montpellier
ZIP/Postal Code
34298
Country
France
Facility Name
Institut Curie - site de Paris
City
Paris
ZIP/Postal Code
75005
Country
France
Facility Name
Hopital Tenon
City
Paris
ZIP/Postal Code
75020
Country
France
Facility Name
Klinikum rechts der Isar der TU Muenchen
City
Muenchen
State/Province
Bayern
ZIP/Postal Code
81675
Country
Germany
Facility Name
Marienhospital Bottrop gGmbH
City
Bottrop
State/Province
Rheinland Pfalz
ZIP/Postal Code
46236
Country
Germany
Facility Name
Universitaetsklinikum Schleswig-Holstein - Campus Luebeck
City
Luebeck
State/Province
Schleswig Holstein
ZIP/Postal Code
23538
Country
Germany
Facility Name
Helios-Kliniken Berlin-Buch
City
Berlin
ZIP/Postal Code
13125
Country
Germany
Facility Name
Universitaetsklinikum Duesseldorf AoeR
City
Düsseldorf
ZIP/Postal Code
40225
Country
Germany
Facility Name
Universitaetsklinikum Erlangen
City
Erlangen
ZIP/Postal Code
91054
Country
Germany
Facility Name
Kliniken Koeln
City
Koeln
ZIP/Postal Code
51067
Country
Germany
Facility Name
Universitaetsklinikum Leipzig AoeR
City
Leipzig
ZIP/Postal Code
04103
Country
Germany
Facility Name
Klinikum der Universitaet Muenchen - Campus Grosshardern
City
Munich
ZIP/Postal Code
81377
Country
Germany
Facility Name
Universitaetsklinikum Muenster
City
Müenster
ZIP/Postal Code
48149
Country
Germany
Facility Name
Haematologisch-Onkologische Schwerpunktpraxis
City
Troisdorf
ZIP/Postal Code
53840
Country
Germany
Facility Name
251 General Air Force Hospital
City
Athens
ZIP/Postal Code
11525
Country
Greece
Facility Name
General Hospital of Athens "Alexandra"
City
Athens
ZIP/Postal Code
11528
Country
Greece
Facility Name
General Oncology Hospital of Kifissia " Agioi Anargyroi"
City
Athens
ZIP/Postal Code
14564
Country
Greece
Facility Name
University General Hospital of Heraklion
City
Heraklion
ZIP/Postal Code
71110
Country
Greece
Facility Name
Euromedica General Clinic Thessaloniki
City
Thessaloníki
ZIP/Postal Code
54645
Country
Greece
Facility Name
Rambam Health Care Center
City
Haifa
ZIP/Postal Code
3109601
Country
Israel
Facility Name
Shaare Zedek Medical Center
City
Jerusalem
ZIP/Postal Code
9103102
Country
Israel
Facility Name
Hadassah University Hospital - Ein Kerem
City
Jerusalem
ZIP/Postal Code
9112001
Country
Israel
Facility Name
Sapir Medical Center, Meir Hospital
City
Kfar Saba
ZIP/Postal Code
4428164
Country
Israel
Facility Name
Rabin Medical Center-Beilinson Campus
City
Petah tikva
ZIP/Postal Code
49100
Country
Israel
Facility Name
Chaim Sheba Medical Center
City
Ramat Gan
ZIP/Postal Code
52363
Country
Israel
Facility Name
Tel Aviv Sourasky Medical Center
City
Tel Aviv
ZIP/Postal Code
6423906
Country
Israel
Facility Name
Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo)
City
Monza
State/Province
Milano
ZIP/Postal Code
20900
Country
Italy
Facility Name
IRCCS Centro di Riferimento Oncologico
City
Aviano
State/Province
Pordenone
ZIP/Postal Code
33081
Country
Italy
Facility Name
Ospedale Sacro Cuore Don Calabria
City
Negrar
State/Province
Verona
ZIP/Postal Code
37024
Country
Italy
Facility Name
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
City
Bergamo
ZIP/Postal Code
24127
Country
Italy
Facility Name
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi
City
Bologna
ZIP/Postal Code
40138
Country
Italy
Facility Name
Azienda Ospedaliera Universitaria Arcispedale Sant'Anna
City
Cona
ZIP/Postal Code
44124
Country
Italy
Facility Name
Istituto Nazionale per la Ricerca sul Cancro di Genova
City
Genova
ZIP/Postal Code
16132
Country
Italy
Facility Name
Azienda Ospealiera della Provincia di Lecco
City
Lecco
ZIP/Postal Code
23900
Country
Italy
Facility Name
Azienda Ospedaliera Ospedali Riuniti Papardo-Piemonte
City
Messina
ZIP/Postal Code
98158
Country
Italy
Facility Name
Ospedale San Raffaele
City
Milano
ZIP/Postal Code
20132
Country
Italy
Facility Name
Fondazione IRCCS Istituto Nazionale dei Tumori
City
Milano
ZIP/Postal Code
20133
Country
Italy
Facility Name
IEO Istituto Europeo di Oncologia
City
Milano
ZIP/Postal Code
20141
Country
Italy
Facility Name
A.O.U. Policlinico di Modena
City
Modena
ZIP/Postal Code
41124
Country
Italy
Facility Name
Istituto Nazionale Tumori Fondazione G. Pascale
City
Napoli
ZIP/Postal Code
80131
Country
Italy
Facility Name
IOV - Istituto Oncologico Veneto IRCCS
City
Padova
ZIP/Postal Code
35128
Country
Italy
Facility Name
Azienda Ospedaliero Universitaria di Parma
City
Parma
ZIP/Postal Code
43100
Country
Italy
Facility Name
Fondazione IRCCS Policlinico San Matteo
City
Pavia
ZIP/Postal Code
27100
Country
Italy
Facility Name
Azienda Ospedaliero Universitaria Pisana
City
Pisa
ZIP/Postal Code
56126
Country
Italy
Facility Name
Azienda Ospedaliera Città della Salute e della Scienza di Torino
City
Torino
ZIP/Postal Code
10126
Country
Italy
Facility Name
Fukushima Medical University Hospital
City
Fukushima-shi
State/Province
Fukushima-Ken
ZIP/Postal Code
960-1295
Country
Japan
Facility Name
Kindai University Hospital
City
Osakasayama-shi
State/Province
Osaka-Fu
ZIP/Postal Code
589-8511
Country
Japan
Facility Name
Kindai University Hospital
City
Ōsakasayama-shi
State/Province
Osaka-Fu
ZIP/Postal Code
589-8511
Country
Japan
Facility Name
National Cancer Center Hospital
City
Chuo Ku
State/Province
Tokyo-To
ZIP/Postal Code
104-0045
Country
Japan
Facility Name
NHO Shikoku Cancer Center
City
Ehime
ZIP/Postal Code
791-0280
Country
Japan
Facility Name
NHO Kyushu Cancer Center
City
Fukuoka
ZIP/Postal Code
811-1395
Country
Japan
Facility Name
Hiroshima City Hiroshima Citizens Hospital
City
Hiroshima
ZIP/Postal Code
730-8518
Country
Japan
Facility Name
NHO Hokkaido Cancer Center
City
Hokkaido
ZIP/Postal Code
003-0804
Country
Japan
Facility Name
Hyōgo College of Medicine Hospital
City
Hyōgo
ZIP/Postal Code
663-8501
Country
Japan
Facility Name
St. Marianna University School of Medicine Hospital
City
Kanagawa
ZIP/Postal Code
216-8511
Country
Japan
Facility Name
Kanagawa Cancer Center
City
Kanagawa
ZIP/Postal Code
241-8515
Country
Japan
Facility Name
Kyoto University Hospital
City
Kyoto
ZIP/Postal Code
606-8507
Country
Japan
Facility Name
Tohoku University Hospital
City
Miyagi
ZIP/Postal Code
980-8574
Country
Japan
Facility Name
Aichi Cancer Center Hospital
City
Nagoya
ZIP/Postal Code
464-8681
Country
Japan
Facility Name
Niigata Cancer Center Hospital
City
Niigata
ZIP/Postal Code
951-8566
Country
Japan
Facility Name
Okayama University Hospital
City
Okayama
ZIP/Postal Code
700-8558
Country
Japan
Facility Name
NHO Osaka National Hospital
City
Osaka
ZIP/Postal Code
540-0006
Country
Japan
Facility Name
Osaka International Cancer Institute
City
Osaka
ZIP/Postal Code
541-8567
Country
Japan
Facility Name
Saitama Cancer Center
City
Saitama
ZIP/Postal Code
362-0806
Country
Japan
Facility Name
Shizuoka Cancer Center
City
Shizuoka
ZIP/Postal Code
411-8777
Country
Japan
Facility Name
Toranomon Hospital
City
Tokyo
ZIP/Postal Code
105-8470
Country
Japan
Facility Name
The Cancer Institute Hospital of JFCR
City
Tokyo
ZIP/Postal Code
135-8550
Country
Japan
Facility Name
Tokyo Medical University Hospital
City
Tokyo
ZIP/Postal Code
160-0023
Country
Japan
Facility Name
Chungbuk National University Hospital
City
Cheongju-si
State/Province
Chungcheongbuk-do
ZIP/Postal Code
28644
Country
Korea, Republic of
Facility Name
Inha University Hospital
City
Incheon
State/Province
Gyeonggi-do
ZIP/Postal Code
22332
Country
Korea, Republic of
Facility Name
Seoul National University Bundang Hospital
City
Seongnam-si
State/Province
Gyeonggi-do
ZIP/Postal Code
13620
Country
Korea, Republic of
Facility Name
The Catholic University of Korea, St. Vincent's Hospital
City
Suwon-si
State/Province
Gyeonggi-do
ZIP/Postal Code
16247
Country
Korea, Republic of
Facility Name
Ajou University Hospital
City
Suwon
State/Province
Gyeonggi-do
ZIP/Postal Code
16499
Country
Korea, Republic of
Facility Name
Kyungpook National University Chilgok Hospital
City
Daegu
ZIP/Postal Code
41404
Country
Korea, Republic of
Facility Name
National Cancer Center
City
Goyang-si
ZIP/Postal Code
10408
Country
Korea, Republic of
Facility Name
Korea University Anam Hospital
City
Seoul
ZIP/Postal Code
02841
Country
Korea, Republic of
Facility Name
Seoul National University Hospital
City
Seoul
ZIP/Postal Code
03080
Country
Korea, Republic of
Facility Name
Severance Hospital, Yonsei University
City
Seoul
ZIP/Postal Code
03772
Country
Korea, Republic of
Facility Name
Asan Medical Center
City
Seoul
ZIP/Postal Code
05505
Country
Korea, Republic of
Facility Name
Samsung Medical Center
City
Seoul
ZIP/Postal Code
06351
Country
Korea, Republic of
Facility Name
The Catholic University of Korea, Seoul St. Mary's Hospital
City
Seoul
ZIP/Postal Code
06591
Country
Korea, Republic of
Facility Name
ICO Badalona - Hospital Universitari Germans Trias i Pujol
City
Badalona
State/Province
Barcelona
ZIP/Postal Code
08916
Country
Spain
Facility Name
ICO l'Hospitalet - Hospital Duran i Reynals
City
L'Hospitalet De Llobregat
State/Province
Barcelona
ZIP/Postal Code
08908
Country
Spain
Facility Name
Hospital de Especialidades de Jerez de la Frontera
City
Jerez De La Frontera
State/Province
Cádiz
ZIP/Postal Code
11407
Country
Spain
Facility Name
Complejo Hospitalario Universitario A Coruña
City
A Coruña
State/Province
La Coruña
ZIP/Postal Code
15006
Country
Spain
Facility Name
Hospital Universitario de Canarias
City
San Cristobal de la Laguna
State/Province
Tenerife
ZIP/Postal Code
38320
Country
Spain
Facility Name
Hospital Infanta Cristina
City
Badajoz
ZIP/Postal Code
06007
Country
Spain
Facility Name
Hospital Quironsalud Barcelona
City
Barcelona
ZIP/Postal Code
08023
Country
Spain
Facility Name
Hospital Universitari Vall d'Hebron
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Hospital Clinic de Barcelona
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Name
Hospital del Mar
City
Barcelona
ZIP/Postal Code
8003
Country
Spain
Facility Name
Hospital Universitari Arnau de Vilanova
City
Lleida
ZIP/Postal Code
25198
Country
Spain
Facility Name
Hospital General Universitario Gregorio Marañon
City
Madrid
ZIP/Postal Code
28007
Country
Spain
Facility Name
MD Anderson Cancer Centre
City
Madrid
ZIP/Postal Code
28033
Country
Spain
Facility Name
Hospital Universitario Clinico San Carlos
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Hospital Clinico Universitario Virgen de la Victoria
City
Málaga
ZIP/Postal Code
29010
Country
Spain
Facility Name
Hospital Universitario de Salamanca
City
Salamanca
ZIP/Postal Code
37370
Country
Spain
Facility Name
Hospital Universitario Virgen Macarena
City
Sevilla
ZIP/Postal Code
41009
Country
Spain
Facility Name
Hospital Universitario Virgen del Rocio
City
Sevilla
ZIP/Postal Code
41013
Country
Spain
Facility Name
Instituto Valenciano de Oncologia IVO
City
Valencia
ZIP/Postal Code
46009
Country
Spain
Facility Name
Hospital Universitario Miguel Servet
City
Zaragoza
ZIP/Postal Code
50009
Country
Spain
Facility Name
Acibadem Adana Hospital
City
Adana
ZIP/Postal Code
01130
Country
Turkey
Facility Name
Adana Numune Training and Research Hospital
City
Adana
ZIP/Postal Code
01370
Country
Turkey
Facility Name
Ankara Yildirim Beyazit Uni. Med. Fac.Ankara City Hospital
City
Ankara
ZIP/Postal Code
6800
Country
Turkey
Facility Name
Akdeniz University Medical Faculty
City
Antalya
ZIP/Postal Code
07058
Country
Turkey
Facility Name
Uludag University Medical Faculty
City
Bursa
ZIP/Postal Code
16059
Country
Turkey
Facility Name
Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty
City
Istanbul
ZIP/Postal Code
34098
Country
Turkey
Facility Name
Bakirkoy Dr. Sadi Konuk Teaching and Research Hospital
City
Istanbul
ZIP/Postal Code
34147
Country
Turkey
Facility Name
Medipol University Medical Faculty
City
Istanbul
ZIP/Postal Code
34214
Country
Turkey
Facility Name
Medical Park Goztepe Hospital
City
Istanbul
ZIP/Postal Code
34732
Country
Turkey
Facility Name
Istanbul Medeniyet Uni Goztepe Training & Research Hospital
City
Istanbul
ZIP/Postal Code
34854
Country
Turkey
Facility Name
Kartal Lutfi Kirdar Research and Training Hospital
City
Istanbul
ZIP/Postal Code
34890
Country
Turkey
Facility Name
Izmir Medicalpark Hospital
City
İzmir
ZIP/Postal Code
35530
Country
Turkey
Facility Name
Konya Necmettin Erbakan University Meram Faculty of Medicine
City
Konya
ZIP/Postal Code
42080
Country
Turkey
Facility Name
Sakarya Traning and Research Hospital
City
Sakarya
ZIP/Postal Code
54187
Country
Turkey
Facility Name
Medical Park Samsun Hastanesi
City
Samsun
ZIP/Postal Code
55200
Country
Turkey
Facility Name
Namik Kemal University
City
Tekirdağ
ZIP/Postal Code
59100
Country
Turkey
Facility Name
Royal Cornwall Hospital
City
Truro
State/Province
Cornwall
ZIP/Postal Code
TR1 3LJ
Country
United Kingdom
Facility Name
Royal Devon and Exeter Hospital (Wonford)
City
Exeter
State/Province
Devon
ZIP/Postal Code
EX2 5DW
Country
United Kingdom
Facility Name
Derriford Hospital
City
Plymouth
State/Province
Devon
ZIP/Postal Code
PL6 8BQ
Country
United Kingdom
Facility Name
Aberdeen Royal Infirmary
City
Aberdeen
State/Province
Grampian Region
ZIP/Postal Code
AB25 2ZB
Country
United Kingdom
Facility Name
Queen Mary University of London
City
London
State/Province
Greater London
ZIP/Postal Code
EC1M 6BQ
Country
United Kingdom
Facility Name
University College London Hospitals
City
London
State/Province
Greater London
ZIP/Postal Code
NW1 2PG
Country
United Kingdom
Facility Name
Sarah Cannon Research Institute UK
City
London
State/Province
Greater London
ZIP/Postal Code
W1G 6AD
Country
United Kingdom
Facility Name
Western General Hospital
City
Edinburgh
State/Province
Lothian Region
ZIP/Postal Code
EH4 2XU
Country
United Kingdom
Facility Name
Nottingham University Hospitals City Campus
City
Nottingham
State/Province
Nottinghamshire
ZIP/Postal Code
NG5 1PB
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD Sharing Time Frame
Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD Sharing Access Criteria
Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
IPD Sharing URL
https://vivli.org/ourmember/daiichi-sankyo/
Citations:
PubMed Identifier
37086745
Citation
Andre F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G, Lima JP, Aksoy S, Gavila Gregori J, De Laurentiis M, Bianchini G, Roylance R, Miyoshi Y, Armstrong A, Sinha R, Ruiz Borrego M, Lim E, Ettl J, Yerushalmi R, Zagouri F, Duhoux FP, Fehm T, Gambhire D, Cathcart J, Wu C, Chu C, Egorov A, Krop I. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 May 27;401(10390):1773-1785. doi: 10.1016/S0140-6736(23)00725-0. Epub 2023 Apr 20.
Results Reference
result

Learn more about this trial

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

We'll reach out to this number within 24 hrs